Open Access

Trypanocidal activity of salinomycin is due to sodium influx followed by cell swelling

Parasites & Vectors20136:78

https://doi.org/10.1186/1756-3305-6-78

Received: 8 January 2013

Accepted: 18 March 2013

Published: 21 March 2013

Abstract

Background

The few currently available drugs for treatment of African trypanosomiasis are outdated and show problems with toxicity and resistance. Hence, there is an urgent need for the discovery and development of new anti-trypanosomal agents.

Findings

In this study, the ionophorous antibiotic salinomycin was investigated for its trypanocidal activity in vitro using culture-adapted bloodstream forms of Trypanosoma brucei. The concentrations of salinomycin to reduce the growth rate by 50% and to kill the parasites were 0.31 μM and 1 μM, respectively. The trypanocidal action of the ionophore was shown to be the result of an influx of Na+ resulting in an increased intracellular Na+ concentration followed by cell swelling. This mode of action differs from the mechanism for the anti-cancer activity of salinomycin reported to be by induction of apoptosis.

Conclusion

Here we have shown that salinomycin is an effective agent against bloodstream forms of T. brucei and might be a potential candidate for treatment of African trypanosomiasis.

Keywords

African trypanosomiasis Trypanosoma brucei SalinomycinDrug screening

Findings

Background

African trypanosomes are the etiological agents of sleeping sickness in humans and nagana disease in cattle. The parasites are transmitted by the bite of infected tsetse flies and live and multiply in the blood and tissue fluids of their mammalian hosts. Both sleeping sickness and nagana disease occur in sub-Saharan Africa between 14° North and 20° South latitude, the distribution area of tsetse flies [1]. In this so-called tsetse belt, millions of people and cattle are at risk of getting infected with the parasites [2, 3]. In addition, it is estimated that nagana disease costs the affected African countries over 1 billion USD per year [3]. Chemotherapy of African trypanosomiasis still relies on a few drugs developed decades ago, most of which show poor efficacy and significant toxicity, and are being increasingly subject to drug resistance [4]. Thus, new drugs are urgently needed for chemotherapy of sleeping sickness and nagana disease. One approach for the discovery of new drugs for treatment of African trypanosomiasis is the screening of existing drugs for trypanocidal activities [5].

Salinomycin (Figure 1) is a carboxylic polyether antibiotic produced by a strain of Streptomyces albus[6]. It is a monovalent cation ionophore mediating the transport of Na+, K+ and Rb+ (but not of Cs+, Mg2+, Ca2+ and Sr2+) across organic phases [7]. The antibiotic is widely used as a food supplement to control coccidiosis in poultry [8, 9] and has recently received attention as a novel cancer drug candidate [10]. However, compounds displaying anti-cancer activity usually also exhibit strong trypanocidal activity [1113]. In this study, we investigated the trypanocidal activity of salinomycin and the underlying mechanism of action of the antibiotic using bloodstream forms of Trypanosoma brucei.
Figure 1

Structure of salinomycin.

Methods

The trypanocidal activity of salinomycin was determined with bloodstream forms of the T. brucei clone 427–221 [14] while the general cytotoxicity of the ionophore was evaluated with human HL-60 cells and normal PBMCs (peripheral blood mononuclear cells). Cells were seeded in 24-well plates in a final volume of 1 ml of appropriate culture medium (trypanosomes: Baltz medium [15]; human cells: RPMI medium [16]) supplemented with 16.7% (v/v) heat-inactivated foetal bovine serum and containing various concentrations of salinomycin (10-4 to 10-9 M) and 1% DMSO. Wells containing medium and 1% DMSO served as controls. The initial cell densities were 1 × 104/ml for trypanosomes, 1 × 105/ml for HL-60 cells and 5 × 105/ml for PBMCs. After 24 h incubation, 100 μl of a 0.44 mM resazurin solution prepared in PBS was added and the cells were incubated for a further 48 h. Thereafter, the plates were read on a microplate reader using a test wavelength of 570 nm and a reference wavelength of 630 nm. The 50% growth inhibition (GI50) value (trypanosomes and HL-60 cells) and the 50% effective concentration (EC50) value (PBMCs), i.e., the concentration of salinomycin necessary to reduce the growth rate of cells by 50% or to cause an effect in 50% of cells compared to the control, were determined from mean values using the 4-parameter logistic model [17]. The following formula for the 4-parameter logistic model was used: Y = {[a-d]/[1 + (X/c) b ]} + d, where Y is the response, X is the concentration, a is the lower asymptote (lower plateau), d is the upper asymptote (upper plateau), b is the slope factor (Hill factor) and c is the GI50/EC50 value. The minimum inhibitory concentration (MIC) value, i.e. the concentration of salinomycin at which all cells were killed, was determined microscopically by inspecting each well thoroughly for the presence of any motile trypanosomes or unlysed HL-60s or PBMCs.

Changes in cell volume were measured using a previously described light scattering method [18]. Bloodstream forms of T. brucei were seeded at a density of 5 × 107 cells/ml in 96-well plates in a final volume of 200 μl culture medium containing 100 μM salinomycin and 0.5% DMSO (test) or 0.5% DMSO alone (control). Absorbance of the cultures was measured at 490 nm every 15 min. A decrease in absorbance corresponded to an increase in cell volume.

Cell morphology changes were examined by light microscopy. Briefly, bloodstream forms of T. brucei were treated at a density of 5 × 107 cells/ml with 100 μM salinomycin and 0.5% DMSO (test) or 0.5% DMSO alone (control). After 1 h incubation, cells were fixed with 2% formaldehyde/0.05% glutaraldehyde in PBS, spread onto slides and air dried. The smears were stained with May-Grünwald staining solution and then imaged with a Zeiss Axioplan 2 fluorescence microscope using a Plan-Apochromat 100×/1.4 oil objective.

The intracellular level of Na+ was monitored with Sodium Green™ tetraacetate, a cell-permeant indicator for the fluorometric determination of Na+ concentration. The probe can freely diffuse across cell membranes and is intracellularly converted into the Na+-responsive acidic form by esterases. Trypanosomes were incubated at a density of 5 × 107 cells/ml with 100 μM salinomycin and 0.5% DMSO (test) or 0.5% DMSO alone (control) in the presence of 4 μM Sodium Green™ tetraacetate for 1 h. After washing twice with culture medium, cells were then immediately analysed by flow cytometry using a BD Accuri C6 flow cytometer. The excitation wavelength was 488 nm and the filter set was 530/30 nm. Gates were set to exclude cell fragments and debris from the analysis, and 50,000 gated cells were analysed.

Results and discussion

Salinomycin showed a dose-dependent effect on the growth of T. brucei bloodstream forms with a GI50 value of 0.17 μM and a MIC value of 1 μM (Figure 2). The ionophore displayed similar cytotoxic activity against leukaemic HL-60 cells with a GI50 value of 0.29 μM and a MIC value of 1 μM (Figure 2). Similar antiproliferative activity has been recently reported for various other cancer cells including human promyelocytic leukaemia cells (IC50 = 0.44 μM [19]), human colon adenocarcinoma cells (IC50 = 1.11 μM [19]) and VCaP prostate carcinoma cells (EC50 = 0.38 μM [20]). In contrast to the effect on cancer cells, it was reported that salinomycin is 10–100 times less cytotoxic against non-malignant cells [19, 20]. In fact, salinomycin exhibited only low cytotoxicity against normal PBMCs with an EC50 value of 29.9 μM and a MIC value of 100 μM (Figure 2). This latter finding indicates that the ratio for cytotoxic/trypanocidal activity (selectivity index) for salinomycin is in a moderate range.
Figure 2

Trypanocidal and cytotoxic effects of salinomycin. Bloodstream forms of T. brucei (red squares), HL-60 cells (green circles) and PBMCs (blue triangles) were incubated with varying concentrations of salinomycin. After 72 h of culture, cell viability and proliferation were determined with the colorimetric dye resazurin. Mean values ± SD of three (PBMCs) or four (T. brucei and HL-60) experiments are shown. Dose–response curves were calculated from mean values using the 4-parameter logistic model.

One obvious mechanism of action of salinomycin would be its effect as an ionophore on the depolarisation of membrane potentials. By using the fluorescent probe 3,3’-dihexyloxycarbocyanine, however, it was found that salinomycin did not affect the membrane potential of bloodstream forms of T. brucei (data not shown). This observation is in agreement with previous findings that valinomycin also did not influence the membrane potential of trypanosomes, although the parasites are extremely sensitive to this ionophore [21].

Another possible mechanism of action of salinomycin could be that the ionophore increases the intracellular cation level followed by a quick entry of water which would lead to cell swelling and damage of intracellular structures. Changes in cell volume can be monitored spectrophotometrically by following the absorbance of the cell suspension at 490 nm. Incubation of bloodstream forms of T. brucei with 100 μM salinomycin resulted in a decrease of absorbance over time while the absorbance of control cultures did not change (Figure 3). It should be noted that a much higher concentration of salinomycin was needed (100 μM compared to 1 μM necessary to kill all cells in the growth inhibition assay shown in Figure 2) in order to observe a measurable effect on the swelling of trypanosomes in a short period of time. This is because that at high cell density, which is required for the recording of changes in cell volume, bloodstream forms of T. brucei do not survive for a very long time in culture. The decrease in absorbance corresponded to cell swelling as judged from visual observation by light microscopy. Parasites treated for 1 h with 100 μM salinomycin lost the normal elongated shape of trypanosomes and appeared as rounded up cells (Figure 4). The only monovalent cations present within bloodstream forms of T. brucei and in the culture medium are Na+ and K+. Thus, only these may be involved in the cell swelling observed in the presence of salinomycin. As bloodstream forms of T. brucei are low-Na+ and high-K+ cells [22], only a salinomycin-mediated transport of Na+ from the exterior to the interior could explain the observed cell swelling. To prove that the cause of the swelling was indeed due to an increased intracellular Na+ level, the concentration of Na+ was determined with the fluorescent probe Sodium Green™ tetraacetate. Subsequent flow cytometry revealed that trypanosomes treated with 100 μM salinomycin for 1 h had a much higher fluorescence signal than control cells (Figure 5). The median fluorescence intensity signal for salinomycin-treated parasites was 2223 ± 164 (n = 3) and for control parasites it was 1050 ± 345 (n = 3). This result indicates that upon incubation with salinomycin, the intracellular Na+ concentration was raised more than twofold in the trypanosomes from 13.7 mM [22] to about 30 mM. This increase in Na+ concentration is enough to explain the swelling of trypanosomes by entry of water. For instance, subjection of bloodstream forms of T. brucei to a reduction in osmolarity from 300 to 150 mOsm (which in turn can be regarded as a twofold increase in the intracellular concentration of solute particles) results in a dramatic initial swelling of the cells [23].
Figure 3

Effect of salinomycin on the cell volume of bloodstream forms of T. brucei . Trypanosomes (5 × 107 cell/ml) were incubated in the absence (circles) or presence (squares) of 100 μM salinomycin in culture medium. Every 15 min the absorbance at 490 nm was measured. Note that a decrease in absorbance corresponds to an increase in cell volume. Mean values ± SD of three experiments are shown.

Figure 4

Effect of salinomycin on the morphology of bloodstream forms of T. brucei . Trypanosomes (5 × 107 cell/ml) were incubated in the absence (A) or presence (B) of 100 μM salinomycin for 1 h. Formaldehyde/glutaraldehyde-fixed cells were spread onto slides, air dried and stained with May-Grünwald staining solution. A representative experiment out of three is shown.

Figure 5

Effect of salinomycin on intracellular Na + levels in bloodstream forms of T. brucei . Trypanosomes (5 × 107 cell/ml) were incubated with 4 μM Sodium Green™ tetraacetate in the absence (black line) or presence (red line) of 100 μM salinomycin. After 1 h incubation, trypanosomes were washed with culture medium and analysed by flow cytometry. A representative experiment out of three is shown.

Conclusion

This study has demonstrated that the ionophore salinomycin displays trypanocidal activity by a mechanism involving increased Na+ influx followed by subsequent cell swelling which is probably due to the uptake of water. This mechanism is different from the mode of action reported for the anti-cancer activity of salinomycin. Recent research has shown that salinomycin induces apoptosis in cancer cells by different mechanisms, which include increasing the intracellular levels of reactive oxygen species (ROS) [24] and inhibiting the Wnt signalling pathway [25]. However, we did not find any evidence that the trypanocidal activity of salinomycin is associated with the induction of apoptosis in bloodstream forms of T. brucei (data not shown).

Importantly, salinomycin can be administered orally whereas most of the current drugs used for treatment of African trypanosomiasis have to be given parenterally. Before developing salinomycin into an anti-trypanosomal agent, animal experiments are needed to establish the in vivo trypanocidal activity of the ionophore. However, a selectivity index of 10–100 may be inadequate for proceeding with animal studies as it is recommended that such animal experiments should only be pursued if the selectivity index is greater than 100 [26]. Despite this, salinomycin may serve as a lead for the development of derivatives with improved trypanocidal activities. In addition, the ionophore could be used in combination with current anti-trypanosomal drugs. In recent years, such a drug combination regime (eflornithine/nifurtimox) has been successfully introduced for the treatment of human African sleeping sickness [27].

Declarations

Acknowledgements

We thank Dr Andrew Goldson for his help in preparing the graphs of the flow cytometry analysis.

Authors’ Affiliations

(1)
BioMedical Research Centre, Norwich Medical School, University of East Anglia

References

  1. Molyneux DH, Pentreath V, Doua F: African trypanosomiasis in man. Manson’s Tropical Diseases. Edited by: Cook GC. 1996, London: W.B. Saunders, 1171-1196. 20Google Scholar
  2. World Health Organization: Trypanosomiasis, human African (sleeping sickness). World Health Org Fact Sheet. 2012, 259:http://www.who.int/mediacentre/factsheets/fs259/en/,Google Scholar
  3. Kristjanson PM, Swallow BM, Rowlands GJ, Kruska RL, de Leeuw PN: Measuring the costs of African animal trypanosomiasis, the potential benefits of control and returns to research. Agr Sys. 1999, 59: 79-98. 10.1016/S0308-521X(98)00086-9.View ArticleGoogle Scholar
  4. Delespaux V, de Koning HP: Drugs and drug resistance in African trypanosomiasis. Drug Resist Updat. 2007, 10: 30-50. 10.1016/j.drup.2007.02.004.View ArticlePubMedGoogle Scholar
  5. Caffrey CR, Steverding D: Recent initiatives and strategies to developing new drugs for tropical parasitic diseases. Expert Opin Drug Discov. 2008, 3: 173-186. 10.1517/17460441.3.2.173.View ArticlePubMedGoogle Scholar
  6. Miyazaki Y, Shibuya M, Sugawara H, Kawaguchi O, Hirose C, Nagatsu J, Esumi S: Salinomycin, a new polyether antibiotic. J Antibiot (Tokyo). 1974, 27: 814-821. 10.7164/antibiotics.27.814.View ArticleGoogle Scholar
  7. Mitani M, Yamanishi T, Miyazaki Y: Salinomycin: a new monovalent cation ionophore. Biochem Biophys Res Commun. 1975, 66: 1231-1236. 10.1016/0006-291X(75)90490-8.View ArticlePubMedGoogle Scholar
  8. Chapman HD: Use of anticoccidial drugs in broiler chickens in the USA: analysis for the years 1995 to 1999. Poult Sci. 2001, 80: 572-580.View ArticlePubMedGoogle Scholar
  9. Chapman HD, Johnson ZB: Use of antibiotics and roxarsone in broiler chickens in the USA: analysis for the years 1995 to 2000. Poult Sci. 2002, 81: 356-364.View ArticlePubMedGoogle Scholar
  10. Huczynski A: Salinomycin: a new cancer drug candidate. Chem Biol Drug Des. 2012, 79: 235-238. 10.1111/j.1747-0285.2011.01287.x.View ArticlePubMedGoogle Scholar
  11. Deterding A, Dungey FA, Thompson KA, Steverding D: Anti-trypanosomal activities of DNA topoisomerase inhibitors. Acta Trop. 2005, 93: 311-316. 10.1016/j.actatropica.2005.01.005.View ArticlePubMedGoogle Scholar
  12. Steverding D, Wang X: Trypanocidal activity of the proteasome inhibitor and anti-cancer drug Bortezomib. Parasit Vectors. 2009, 2: 29-10.1186/1756-3305-2-29.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Steverding D, Wang X, Potts BC, Palladino MA: Trypanocidal activity of β-lactone-γ-lactam proteasome inhibitors. Planta Med. 2012, 78: 131-134. 10.1055/s-0031-1280315.View ArticlePubMedGoogle Scholar
  14. Hirumi H, Hirumi K, Doyle JJ, Cross GAM: In vitro cloning of animal-infective bloodstream forms of Trypanosoma brucei. Parasitology. 1980, 80: 371-382. 10.1017/S0031182000000822.View ArticlePubMedGoogle Scholar
  15. Baltz T, Baltz D, Giroud C, Crockett J: Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense. EMBO J. 1985, 4: 1273-1277.PubMed CentralPubMedGoogle Scholar
  16. Moore GE, Gerner RE, Franklin HA: Culture of normal human leukocytes. J Am Med Assoc. 1967, 199: 519-524. 10.1001/jama.1967.03120080053007.View ArticleGoogle Scholar
  17. Finney DJ: Statistical method in biological assay. 1978, London: Charles Griffin & Co, 3Google Scholar
  18. Park JH, Schofield PJ, Edwards MR: Giardia intestinalis: volume recovery in response to cell swelling. Exp Parasitol. 1997, 86: 19-28. 10.1006/expr.1996.4130.View ArticlePubMedGoogle Scholar
  19. Huczyński A, Janczak J, Antoszczak M, Wietrzyk J, Maj E, Brzezinski B: Antiproliferative activity of salinomycin and its derivatives. Bioorg Med Chem Lett. 2012, 22: 7146-7150. 10.1016/j.bmcl.2012.09.068.View ArticlePubMedGoogle Scholar
  20. Ketola K, Hilvo M, Hyötyläinen T, Vuoristo A, Ruskeepää AL, Orešič M, Kallioniemi O, Iljin K: Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Can. 2012, 106: 99-106. 10.1038/bjc.2011.530.View ArticleGoogle Scholar
  21. Mosimann M, Goshima S, Wenzler T, Lüscher A, Uozumi N, Mäser P: A Trk/HKT-type K+ transporter from Trypanosoma brucei. Eukaryot Cell. 2010, 9: 539-546. 10.1128/EC.00314-09.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Nolan DP, Voorheis HP: Factors that determine the plasma-membrane potential in bloodstream forms of Trypanosoma brucei. Eur J Biochem. 2000, 267: 4615-4623. 10.1046/j.1432-1327.2000.01477.x.View ArticlePubMedGoogle Scholar
  23. Bassarak B, Uzcátegui NL, Schönfeld C, Duszenko M: Functional characterization of three aquaglyceroporins from Trypanosoma brucei in osmoregulation and glycerol transport. Cell Physiol Biochem. 2011, 27: 411-420. 10.1159/000327968.View ArticlePubMedGoogle Scholar
  24. Kim KY, Yu SN, Lee SY, Chun SS, Choi YL, Park YM, Song CS, Chatterjee B, Ahn SC: Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophys Res Commun. 2011, 413: 80-86. 10.1016/j.bbrc.2011.08.054.View ArticlePubMedGoogle Scholar
  25. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA: Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA. 2011, 108: 13253-13257. 10.1073/pnas.1110431108.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Nwaka S, Hudson A: Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov. 2006, 5: 941-955. 10.1038/nrd2144.View ArticlePubMedGoogle Scholar
  27. Simarro PP, Franco J, Diarra A, Postigo JA, Jannin J: Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Parasitology. 2012, 139: 842-846. 10.1017/S0031182012000169.View ArticlePubMedGoogle Scholar

Copyright

© Steverding and Sexton; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Advertisement